Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESIRED
2024-519562-48-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deferoxamine in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Number of endothelial precursor cells after intermittent hypoxia exposure. Planned start Jan 2025; status: authorised.
02
Drugs
deferoxamine
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2024-519562-48-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519562-48-00.